KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Receivables - Other (2016 - 2025)

Historic Receivables - Other for Bristol Myers Squibb (BMY) over the last 17 years, with Q4 2025 value amounting to $192.0 million.

  • Bristol Myers Squibb's Receivables - Other fell 8893.37% to $192.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $192.0 million, marking a year-over-year decrease of 8893.37%. This contributed to the annual value of $192.0 million for FY2025, which is 8893.37% down from last year.
  • Per Bristol Myers Squibb's latest filing, its Receivables - Other stood at $192.0 million for Q4 2025, which was down 8893.37% from $1.8 billion recorded in Q3 2025.
  • In the past 5 years, Bristol Myers Squibb's Receivables - Other ranged from a high of $1.8 billion in Q3 2025 and a low of $192.0 million during Q4 2025
  • Over the past 5 years, Bristol Myers Squibb's median Receivables - Other value was $1.4 billion (recorded in 2021), while the average stood at $1.2 billion.
  • In the last 5 years, Bristol Myers Squibb's Receivables - Other surged by 44724.41% in 2021 and then tumbled by 8893.37% in 2025.
  • Bristol Myers Squibb's Receivables - Other (Quarter) stood at $1.4 billion in 2021, then grew by 24.82% to $1.7 billion in 2022, then plummeted by 76.02% to $416.0 million in 2023, then surged by 317.07% to $1.7 billion in 2024, then plummeted by 88.93% to $192.0 million in 2025.
  • Its last three reported values are $192.0 million in Q4 2025, $1.8 billion for Q3 2025, and $1.7 billion during Q2 2025.